By gaining the GMP licence, Helius joins the likes of Douglas Pharmaceuticals and becomes the 20th on Medsafe’s list of medicine manufacturers organisations in New Zealand. “The GMP licencing process has been exhaustive, and rightly so. We’re making medicines, so there is no room for cutting corners. Helius pulled together an internationally- experienced leadership team from both the pharmaceutical and medicinal cannabis industries to successfully achieve this level of compliance,” said Doran.
Medicinal cannabis inhaler
Meanwhile in neighbouring Australia, Lifespot Health (ASX: LSH) is expected to start clinical trials of its Medihale medical cannabis vape device. The company claims their inhaler will “significantly evolve the treatment options for patients both in Australia and overseas.”
Lifespot is seeking to be a leader in the market, and is developing a solid clinical trial program which it aims to launch next year. The firm has viewed cannabis as a medical solution for patients from its inception, and it’s backed that position with the development of its inhaler devices to meet the needs of patients and physicians. It’s a position that aligns not only with medical professionals but also knowledgeable investors such as Cannvalate and MDI,” said Lifespot chief executive officer Matthew Golden as quoted by Small Caps.
